DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00141830 (ClinicalTrials.gov)	August 2005	30/8/2005	Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy	Rheumatoid Arthritis	Drug: Methotrexate plus ERB-041 for 12 weeks;Drug: Placebo for 12 weeks	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	80 Years	All	159	Phase 2	United States;Canada;Hungary;Italy;Mexico;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00141830
(ClinicalTrials.gov)

August 2005

30/8/2005

Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy

Rheumatoid Arthritis

Drug: Methotrexate plus ERB-041 for 12 weeks;Drug: Placebo for 12 weeks

Wyeth is now a wholly owned subsidiary of Pfizer

NULL

Completed

18 Years

80 Years

All

159

Phase 2

United States;Canada;Hungary;Italy;Mexico;Spain